About us

We are building the next-generation of painkillers

With over 25 years of experience in pain research and the pharmaceutical industry, we are dedicated to researching new treatments for serious diseases in areas with significant unmet medical needs and to ensuring these solutions reach the patients who need them most.

Our vision

At Dolinnov, we believe the answer is not in blocking ion channels but in modulating the ion pump that drives neuronal hyperexcitability.

Our mission is to bring the first Precision Pump Modulator to patients suffering from extreme chronic pain and prove that it can be done.

Precision medicine
Broad Potential
application
Outstanding Proof
of Efficacy

Our operating team

Grégoire Serra
Grégoire Serra
CEO & Co-founder
Grégoire Serra
CEO & Co-founder

Grégoire Serra combines dual expertise in science and law to navigate research, innovation, and regulation. With experience in pharma partnerships, technology transfer, and IP, he drives strategic collaborations and accelerates financing to bring academic projects to the clinic.

Dr. Stéphanie
Ventéo
Dr. Stéphanie
Ventéo
Principal Scientific founder
Dr. Stéphanie
Ventéo
Principal Scientific founder

Dr. Stéphanie Ventéo holds a PhD in Neuroscience and is a Research Engineer at INSERM, leading her group at the Institute for Neurosciences of Montpellier. With 25+ years dedicated to the physiology and pathology of the somatosensory system, her expertise drives groundbreaking advances in chronic pain management.

Jean Philippe Annereau
Jean Philippe Annereau
CSO & Co-founder
Jean Philippe Annereau
CSO & Co-founder

Dr. Jean-Philippe Annereau, PhD from École Polytechnique, brings 20+ years in pharma, focused on oncology and rare diseases. CEO of Medetia Pharmaceuticals and former CEO of Alexion R&D France, he has a strong track record in innovation. At Dolinnov, he shapes R&D strategy to accelerate new pain management solutions.

Our scientific advisory board

Pr. Philippe Barthelemy
Pr. Philippe Barthelemy
Molecular and Nano-Chemistry Expert
Pr. Philippe Barthelemy
Molecular and Nano-Chemistry Expert

Professor & Director of the ChemBioPharm team at the University of Bordeaux and the ARNA Laboratory (INSERM U1212/CNRS UMR 5320). Before joining Bordeaux, he held positions at Emory, Duke, and Avignon. With 150+ publications and 21 patents, he is a leading expert in nanochemistry.

Pr. Theodore Price
Pr. Theodore Price
International pain expert
Pr. Theodore Price
International pain expert

World leading pain expert, Ashbel Smith Professor & Director of the Center for Advanced Pain Studies at UT Dallas. His lab focuses on molecular mechanisms of chronic pain & drug development. Co-founder of CerSci, 4E Therapeutics & Doloromics. 170+ publications, 10+ years of NIH funding.

Pr. Nadine Attal
Pr. Nadine Attal
Clinical Specialist in Pain Disorders
Pr. Nadine Attal
Clinical Specialist in Pain Disorders

Neurologist, pain specialist, & professor at Ambroise Paré Hospital. She heads its Pain Evaluation and Treatment Center and is deputy director of INSERM U987. Leading expert in neuropathic pain, she has chaired international guidelines and led numerous clinical trials, earning the Légion d'Honneur.

Pr. Céline Greco
Pr. Céline Greco
Clinical Specialist in Pain Disorders
Pr. Céline Greco
Clinical Specialist in Pain Disorders

Pr. Greco heads the Pain and Palliative Medicine Department at Necker-Enfants Malades Hospital, France's leading pediatric centers, and sits on the National Council for Child Protection. A physician-researcher, she is committed to improving quality of life for children in chronic pain & serious conditions.

Dr. Leen Thielemans
Dr. Leen Thielemans
Chief Development Officer
Dr. Leen Thielemans
Chief Development Officer

Bioengineer, epidemiologist & PhD in Medical Sciences, Leen is CDO at Dolinnov. With 20+ years in R&D from drug discovery to early clinical development, she has led programs at J&J, Shire and Dynacure, with expertise in translational strategy and personalized medicine.

Dr. Jordi Serra
Dr. Jordi Serra
Expert in Microneurography
Dr. Jordi Serra
Expert in Microneurography

Researcherin Clinical Neurophysiology at King's College Hospital, London. A pioneer in microneurography, he co-founded the AAN Pain Section and the Neuropathic Pain Group of the Spanish Society of Neurology. Expert in peripheral nerve pain diagnosis and treatment.

An innovation-driven team

World-class and experienced team with recognized 
KOL Pain Management given its experience in the development of pain treatments

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, CSO & Co-Founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, Principal Scientific founder

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, CSO & Co-founder

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, R&D Strategy & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor
Trust in our project
Trust in our project
Trust in our project
Trust in our project
+3M€ deployed

already deployed on this project

Partners supporting the project

Join the pain management revolution!

Contact us